{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:10:20Z","timestamp":1791414620590,"version":"4.3.3"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroent\u00e9rologie Clinique et Biologique"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.gcb.2009.08.014","type":"journal-article","created":{"date-parts":[[2010,3,11]],"date-time":"2010-03-11T04:56:13Z","timestamp":1268283373000},"page":"218-223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Toxicit\u00e9 s\u00e9v\u00e8re \u00e0 la cap\u00e9citabine li\u00e9e \u00e0 un d\u00e9ficit enzymatique en dihydropyrimidine d\u00e9shydrog\u00e9nase (DPD)"],"prefix":"10.1016","volume":"34","author":[{"given":"S.","family":"Coursier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Martelet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Guillermet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Emptoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Villier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Bontemps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gcb.2009.08.014_bib1","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/CAD.0b013e3282f945aa","article-title":"Capecitabine: an overview of the side effects and their management","volume":"19","author":"Saif","year":"2008","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.gcb.2009.08.014_bib2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clinthera.2005.01.005","article-title":"Capecitabine: a review","volume":"27","author":"Walko","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.gcb.2009.08.014_bib3","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","article-title":"Capecitabine and oxaliplatin for advanced esophagogastric cancer","volume":"358","author":"Cunningham","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gcb.2009.08.014_bib4","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study","volume":"26","author":"Saltz","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gcb.2009.08.014_bib5","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00280-001-0408-0","article-title":"Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients","volume":"49","author":"Poole","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"issue":"Suppl 1","key":"10.1016\/j.gcb.2009.08.014_bib6","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.ejon.2004.06.006","article-title":"Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda)","volume":"8","author":"Mars\u00e9","year":"2004","journal-title":"Eur J Oncol Nurs"},{"key":"10.1016\/j.gcb.2009.08.014_bib7","first-page":"38","article-title":"5-fluorouracil: metabolism and current indications in digestive cancer treatment","volume":"26","author":"Aparicio","year":"2002","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.gcb.2009.08.014_bib8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10269-005-0149-5","article-title":"Pharmacog\u00e9n\u00e9tique du m\u00e9tabolisme des pyrimidines. La dihydropyrimidine d\u00e9shydrog\u00e9nase","volume":"7","author":"Gamelin","year":"2005","journal-title":"Oncologie"},{"key":"10.1016\/j.gcb.2009.08.014_bib9","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1081\/NCN-200027624","article-title":"Pyrimidine degradation defects and severe 5-fluorouracil toxicity","volume":"23","author":"van Kuilenburg","year":"2004","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.gcb.2009.08.014_bib10","first-page":"111","article-title":"Imputation of the unexpected or toxic effects of drugs","volume":"40","author":"Begaud","year":"1985","journal-title":"Actualization of the method used in France. Therapie"},{"key":"10.1016\/j.gcb.2009.08.014_bib11","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1200\/JCO.1997.15.2.808","article-title":"Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study","volume":"15","author":"de Gramont","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gcb.2009.08.014_bib12","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"18","author":"de Gramont","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gcb.2009.08.014_bib13","first-page":"2672","article-title":"Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance","volume":"5","author":"Diasio","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.gcb.2009.08.014_bib14","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","article-title":"Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial","volume":"355","author":"Douillard","year":"2000","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.gcb.2009.08.014_bib15","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJM198507253130407","article-title":"Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity","volume":"313","author":"Tuchman","year":"1985","journal-title":"N Engl J Med."},{"key":"10.1016\/j.gcb.2009.08.014_bib16","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1200\/JCO.1988.6.10.1653","article-title":"Fluorouracil: biochemistry and pharmacology","volume":"6","author":"Pinedo","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gcb.2009.08.014_bib17","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1158\/1535-7163.MCT-06-0327","article-title":"Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance","volume":"5","author":"Morel","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.gcb.2009.08.014_bib18","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1006\/abio.1999.4461","article-title":"Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction","volume":"278","author":"Johnson","year":"2000","journal-title":"Anal Biochem"},{"key":"10.1016\/j.gcb.2009.08.014_bib19","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1023\/A:1011178111295","article-title":"Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer","volume":"12","author":"Volk","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.gcb.2009.08.014_bib20","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1373\/49.10.1661","article-title":"Use of pyrosequencing to detect clinically relevant polymorphisms in dihydropyrimidine dehydrogenase","volume":"49","author":"Ahluwalia","year":"2003","journal-title":"Clin Chem"},{"key":"10.1016\/j.gcb.2009.08.014_bib21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1006\/abio.2002.5666","article-title":"A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency","volume":"306","author":"Ezzeldin","year":"2002","journal-title":"Anal Biochem"},{"key":"10.1016\/j.gcb.2009.08.014_bib22","first-page":"325","article-title":"High-throughput genotyping by DHPLC of the dihydropyrimidine dehydrogenase gene implicated in (fluoro)pyrimidine catabolism","volume":"22","author":"Gross","year":"2003","journal-title":"Int J Oncol"},{"key":"10.1016\/j.gcb.2009.08.014_bib23","first-page":"768","article-title":"Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype","volume":"8","author":"Johnson","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.gcb.2009.08.014_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/PL00008711","article-title":"Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency","volume":"104","author":"van Kuilenburg","year":"1999","journal-title":"Hum Genet"},{"key":"10.1016\/j.gcb.2009.08.014_bib25","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1158\/1078-0432.CCR-03-0374","article-title":"Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test","volume":"10","author":"Mattison","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.gcb.2009.08.014_bib26","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.canlet.2006.09.006","article-title":"5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency","volume":"249","author":"Boisdron-Celle","year":"2007","journal-title":"Cancer Lett"},{"key":"10.1016\/j.gcb.2009.08.014_bib27","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1200\/JCO.2007.13.3934","article-title":"Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer","volume":"26","author":"Gamelin","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gcb.2009.08.014_bib28","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/sj.bjc.6600208","article-title":"Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene","volume":"86","author":"Maring","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.gcb.2009.08.014_bib29","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S1040-8428(98)00036-5","article-title":"Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer--status of the art","volume":"30","author":"Gamelin","year":"1999","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.gcb.2009.08.014_bib30","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1200\/JCO.1999.17.4.1105","article-title":"Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage","volume":"17","author":"Gamelin","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gcb.2009.08.014_bib31","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1158\/1078-0432.CCR-05-2020","article-title":"The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2\u00a0and plasma [2-13C]dihydrouracil","volume":"12","author":"Mattison","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.gcb.2009.08.014_bib32","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1097\/FPC.0b013e32825ea6e3","article-title":"Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation","volume":"17","author":"Mercier","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.gcb.2009.08.014_bib33","first-page":"181","article-title":"Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration","volume":"4","author":"Ezzeldin","year":"2004","journal-title":"Clin Colorectal Cancer"}],"container-title":["Gastroent\u00e9rologie Clinique et Biologique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S039983201000045X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S039983201000045X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T01:51:23Z","timestamp":1759974683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S039983201000045X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S039983201000045X"],"URL":"https:\/\/doi.org\/10.1016\/j.gcb.2009.08.014","relation":{},"ISSN":["0399-8320"],"issn-type":[{"value":"0399-8320","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicit\u00e9 s\u00e9v\u00e8re \u00e0 la cap\u00e9citabine li\u00e9e \u00e0 un d\u00e9ficit enzymatique en dihydropyrimidine d\u00e9shydrog\u00e9nase (DPD)","name":"articletitle","label":"Article Title"},{"value":"Gastroent\u00e9rologie Clinique et Biologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gcb.2009.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}